A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

Michael Rogers, a top official at the Food and Drug Administration, announced Monday he is retiring amid the Trump ...

Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

changes in FDA leadership; and (3) plans to reorganize the Agency and reduce its workforce. On March 25, 2025, Martin "Marty" Makary was confirmed by the Senate to be the 27th Commissioner of Food ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

an oncologist who has previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research (CBER), the agency said on May 6.

The Food and Drug Administration ... has reasserted their leadership" in response to a patchwork of state laws. "Removing these safe ingredients does not change the consumer packaged goods ...